Halozyme Therapeutics (HALO) CFO files Form 3 insider ownership statement

Rhea-AI Filing Summary

HALOZYME THERAPEUTICS, INC. executive Darren Snellgrove, who serves as Senior Vice President and Chief Financial Officer, has filed a Form 3 initial statement of beneficial ownership. The provided data shows no reported buy, sell, or derivative transactions, indicating this filing is primarily administrative and establishes his insider status.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 06/09/2026 - 04:59 PM Accepted by SEC EDGAR 06/09/2026 - 04:59 PM Learn about SEC filing dates

FAQ

What does the Halozyme (HALO) Form 3 filing by Darren Snellgrove represent?

The Form 3 filing records Darren Snellgrove’s status as an insider at Halozyme Therapeutics. It is an initial statement of beneficial ownership and serves as a baseline disclosure under SEC rules for reporting officers and directors.

Did Halozyme CFO Darren Snellgrove report any stock transactions in this Form 3?

The Form 3 data shows no buy, sell, or derivative transactions for Darren Snellgrove. It functions as an initial ownership report, so the emphasis is on establishing insider status rather than detailing recent trading activity in Halozyme shares.

Who is the insider named in the Halozyme (HALO) Form 3 filing?

The insider is Darren Snellgrove, who is identified as Senior Vice President and Chief Financial Officer of Halozyme Therapeutics. His role makes him a reporting person under SEC Section 16, requiring this initial beneficial ownership statement on Form 3.

Does the Halozyme (HALO) Form 3 filing indicate any option exercises or derivative positions?

The summarized Form 3 data lists no derivative transactions or option exercises for Darren Snellgrove. The derivative section is empty, reinforcing that this filing functions as a baseline insider ownership declaration rather than a record of specific equity award activity.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Snellgrove Darren

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/08/2026

3. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ James R. Oehler, Attorney-in-Fact	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)